ProQR Therapeutics N.V. Stock
Price
Target price
€1.78
€1.78
1.020%
0.018
1.020%
€2.81
13:24 / Tradegate
WKN: A12B97 / Symbol: PRQR / Name: ProQR / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. gained 1.020% today.
Our community is currently high on ProQR Therapeutics N.V. with 5 Buy predictions and 0 Sell predictions.
With a target price of 2 € there is a slightly positive potential of 12.36% for ProQR Therapeutics N.V. compared to the current price of 1.78 €.
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
S********** s********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | 1.020% | -3.022% | -9.833% | 3.112% | 14.749% | -58.920% | - |
| Pharming Group | 0.110% | -11.688% | -14.175% | -11.156% | -14.754% | -18.186% | 8.466% |
| Salarius Pharmaceuticals Inc. | 1.850% | 10.553% | -19.266% | -71.613% | -20.721% | -98.176% | -99.994% |
| Ardelyx Inc. | 0.530% | -12.086% | -15.475% | 35.391% | 4.706% | -16.524% | - |
Comments
The comment is under review
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for PRQR provided by MarketBeat